

NIB-103

Name: NIB-103

Synonyms: NA

Indication: Solid Tumor

Company: Noile-Immune Biotech; Takeda Oncology

NIB-103 is originated by Yamaguchi University and developed by Noile-Immune Biotech for the indication of Solid tumours

NIB 102 and NIB 103 licensed to Takeda. Noile-Immune Biotech plans to gain regulatory approval for clinical trials of NIB 102 by the end of 2019 -Immune Biotech and Takeda agree to research and develop CAR-T cells for Solid tumours

CAR-T cell therapy is a type of immunotherapy that uses a patient's own immune system in addition to gene engineering technology.

T cells, a type of immune cells, are collected from a patient's blood, and the T cells are genetically modified to produce artificial receptors on their surface called "chimeric antigen receptors (CARs)". CARs are receptor proteins that allow the T cells to recognize a surface antigen on cancer cells. CAR-T cells are then grown until they number in the billions and infused to the patient after 10 days to two weeks of being cultured in a laboratory.

After the infusion, the T cells multiply in the patients' body, and genetically engineered CAR-T cells recognize surface protein antigens on cancer cells and begin to attack it as a target. Strategic business plan with next generation CAR-T platform against solid cancers.